Your browser doesn't support javascript.
loading
Reply to T.J. Kruser et al.
Chinot, Olivier L; Taphoorn, Martin J B; Bais, Carlos; Bourgon, Richard; Phillips, Heidi S; Abrey, Lauren E; Wick, Wolfgang; Mason, Warren; Henriksson, Roger; Saran, Frank; Nishikawa, Ryo; Cloughesy, Timothy.
Afiliação
  • Chinot OL; Aix-Marseille University, AP-HM, Centre Hospitalier Universitaire Timone, Marseille, France olivier.chinot@ap-hm.fr.
  • Taphoorn MJ; Medical Center Haaglanden, The Hague, and VU University Medical Center, Amsterdam, the Netherlands.
  • Bais C; Genentech, South San Francisco, CA.
  • Bourgon R; Genentech, South San Francisco, CA.
  • Phillips HS; Genentech, South San Francisco, CA.
  • Abrey LE; F. Hoffmann-La Roche, Basel, Switzerland.
  • Wick W; University Medical Center, Heidelberg, Germany.
  • Mason W; Princess Margaret Hospital, Toronto, Ontario, Canada.
  • Henriksson R; Regional Cancer Center Stockholm, Stockholm, and Umeå University, Umeå, Sweden.
  • Saran F; The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.
  • Nishikawa R; Saitama Medical University, Saitama, Japan.
  • Cloughesy T; University of California, Los Angeles, Los Angeles, CA.
J Clin Oncol ; 34(11): 1282-3, 2016 Apr 10.
Article em En | MEDLINE | ID: mdl-26884575

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Encefálicas / Glioblastoma / Antineoplásicos Alquilantes / Inibidores da Angiogênese / Dacarbazina / Anticorpos Monoclonais Humanizados / Quimiorradioterapia / Bevacizumab Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Encefálicas / Glioblastoma / Antineoplásicos Alquilantes / Inibidores da Angiogênese / Dacarbazina / Anticorpos Monoclonais Humanizados / Quimiorradioterapia / Bevacizumab Idioma: En Ano de publicação: 2016 Tipo de documento: Article